Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients
Recruitment status was Recruiting
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Randomized Controlled Trial of Dual-plasmid HBV DNA Vaccine Mediated by in Vivo Electroporation in Chronic Hepatitis B Patients Under Lamivudine Chemotherapy|
- HBV DNA suppression [ Time Frame: Before and after DNA vaccine injection: weeks 0, 60. ] [ Designated as safety issue: Yes ]Suppression of HBV DNA was defined as the >2 log10 decrease of viral load from baseline level.
- Loss of HBeAg [ Time Frame: Weeks 0, 48. ] [ Designated as safety issue: Yes ]HBeAg serum titer was dropped to the detection limit by quantitative determination.
- Appearance of Anti-HBe [ Time Frame: At weeks 0,48. ] [ Designated as safety issue: Yes ]
- HBeAg seroconversion rate [ Time Frame: At weeks 0, 12, 24, 48, 72. ] [ Designated as safety issue: Yes ]loss of HBeAg, or presence of anti-HBe antibody
- The occurrence of YMDD mutants [ Time Frame: At weeks 0, 48, 72. ] [ Designated as safety issue: Yes ]Tyrosine-methionine-aspartate-aspartae (YMDD) mutants were evaluated by means of polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP) and PCR-Sequencing (Invitrogen Ltd. Shanghai,China), at baseline, week 48 and 72. The amino acid (AA) mutations were identified by comparing HBV RT sequences with the genotype-matched consensus sequence generated based on the HBV sequences obtained from genbank. A mutation type was referred to the replacement of the consensus AA of the corresponding genotype with a novel one.
- Viral breakthrough rate [ Time Frame: At weeks 0, 12, 24, 40, 48, 56, 60, 64, 72. ] [ Designated as safety issue: Yes ]On the basis of present Guideline for Management of chronic hepatitis B (CHB), the virologic breakthrough (VBT) was defined as >1 log copies increase in HBV DNA from nadir after an initial virologic response or HBV DNA could be detected again after the previous report of "under the detection limit".
- HBV Ag specific T cell immunity [ Time Frame: At weeks 0, 12, 24, 36, 52, 72. ] [ Designated as safety issue: Yes ]
The enzyme-linked immunosorbent spot (ELISPOT) assay was performed according to the manufacture's protocol in the human IFN-g ELISPOT Set (BD Biosciences, San Diego, CA, USA). The ELISPOT assay for enumeration of antigen-specific IFN-γ-secreting cells (spot forming cells, SFCs) was performed according to the manufacturer's instructions . The number of IFN-γ spots was counted by AID Elispot reader system (AID, Germany). Data are expressed as the mean SFCs/106 PBMC.
Detection of HBV-specific cytotoxic T lymphocyte (CTL) was performed by using flow cytometry (FACS) Calibur (BD Biosciences).
|Study Start Date:||September 2011|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
Experimental: LAM+DNA vaccine
lamivudine (LAM) chemotherapy and DNA vaccine
Biological: HBV DNA vaccine
HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
Placebo Comparator: LAM+Placebo
Each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
lamivudine (LAM) chemotherapy and Placebo
Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
Hepatitis B virus (HBV) affects approximately more than 350 million people worldwide, leading to a wide spectrum of clinical manifestations ranging from an asymptomatic carrier state to self-limited acute infection or fulminant hepatitis to chronic hepatitis with progression to cirrhosis and hepatocellular carcinoma and poses a serious public health problem in endemic counties like China. Current available therapeutic remedies such as interferons and nucleotide/nucleoside analogues are far from satisfactory, for their therapeutic efficacies are limited by the high economic cost with the less tolerable adverse effects or the lack of viral eradicative effect for its long term control of the virus in most of the patients. Viral persistence has been associated with a defect in the development of HBV-specific cellular immunity. Strategies to boost or to broaden the weak virus-specific T-cell response of patients with chronic hepatitis B have been proposed as a means of curing this persistent infection. HBV envelope- and nucleocapsid-based vaccines, new formulations for recombinant vaccines and DNA-based vaccines are currently being assessed in clinical trials, among which DNA vaccine represents a promising immunotherapeutic approach that can induce T-cell mediated antigen specific immunity, owing to its de novo intracellular antigenic protein expression and synthesis.
In clinical trials, although HBV DNA vaccination developed protective antibody responses and antigen-specific CD8 T cells in healthy hepatitis-naive human volunteers, the detectable HBV-specific IFN-γ secreting T cells and decreased serum HBV DNA levels only in some chronic HBV carriers vaccinated with HBV PreS2/S DNA vaccine were limited. One resolution for the main obstacles of the new technique development is to enhance the transfection efficiency of plasmids into host cells; the other is to improve the immunogenicity of DNA vaccine by driving the naïve T cell responses towards the Th1 profile. To tackle the first problem of low transfection rate of DNA vaccine, the investigators had applied the in vivo electroporation (EP) for potency enhancement of HBV DNA vaccine, which dramatically improved the host cell transfection of the plasmids and enabled the DNA vaccine the investigators prepared to elicit both humoral and cellular immune responses in the large body weight animals like rabbit and nonhuman primates. In order to achieve the second goal of immunogenicity improvement of HBV DNA vaccine for its therapeutic usage, the investigators had designed and constructed the Th1 type cytokines (interleukin-2 and interferon-γ) fusion protein expression gene plasmids (pFP), in attempt to direct Th1 bias in favor of cellular immunity augment when being used in combination with HBV DNA vaccine. Both tactics in the form of the dual-plasmids DNA vaccination mediated by EP have been investigated to be safe and efficient to improve the transfection and enhance the immunogenicity of DNA vaccine to the host in both animal models and in phase I,II trials of healthy volunteers and CHB patients.
In order to study the immunotherapeutic effects of EP-mediated dual-plasmids HBV DNA vaccine, the investigators plan to conduct a clinical trial, approved by Chinese State Food and Drug Administration (license number: 2006L03542) with written informed consent from each patient. The trial is a double-blind, randomized, placebo-controlled one in CHB patients with baseline ALT more than 2 times the ULN, for whom antiviral treatment is indicated and who were under the simultaneous lamivudine (LAM) chemotherapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01487876
|Contact: Fuqiang Yang, PhDemail@example.com|
|Beijing, Bejing, China, 10000|
|Contact: Guiqiang Wang, PhD 00861066551122 ext 2597 firstname.lastname@example.org|
|Principal Investigator: Guiqiang Wang, PhD|